Literature DB >> 19615888

Vitamin D receptor gene polymorphisms, serum 25-hydroxyvitamin D levels, and melanoma: UK case-control comparisons and a meta-analysis of published VDR data.

Juliette A Randerson-Moor1, John C Taylor, Faye Elliott, Yu-Mei Chang, Samantha Beswick, Kairen Kukalizch, Paul Affleck, Susan Leake, Sue Haynes, Birute Karpavicius, Jerry Marsden, Edwina Gerry, Linda Bale, Chandra Bertram, Helen Field, Julian H Barth, Isabel Dos Santos Silva, Anthony Swerdlow, Peter A Kanetsky, Jennifer H Barrett, D Timothy Bishop, Julia A Newton Bishop.   

Abstract

We have carried out melanoma case-control comparisons for six vitamin D receptor (VDR) gene single nucleotide polymorphisms (SNPs) and serum 25-hydroxyvitamin D(3) levels in order to investigate the role of vitamin D in melanoma susceptibility. There was no significant evidence of an association between any VDR SNP and risk in 1028 population-ascertained cases and 402 controls from Leeds, UK. In a second Leeds case-control study (299 cases and 560 controls) the FokI T allele was associated with increased melanoma risk (odds ratio (OR) 1.42, 95% confidence interval (CI) 1.06-1.91, p=0.02). In a meta-analysis in conjunction with published data from other smaller data sets (total 3769 cases and 3636 controls), the FokI T allele was associated with increased melanoma risk (OR 1.19, 95% CI 1.05-1.35), and the BsmI A allele was associated with a reduced risk (OR 0.81, 95% CI 0.72-0.92), in each instance under a parsimonious dominant model. In the first Leeds case-control comparison cases were more likely to have a higher body mass index (BMI) than controls (p=0.007 for linear trend). There was no evidence of a case-control difference in serum 25-hydroxyvitamin D(3) levels. In 1043 incident cases from the first Leeds case-control study, a single estimation of serum 25-hydroxyvitamin D(3) level taken at recruitment was inversely correlated with Breslow thickness (p=0.03 for linear trend). These data provide evidence to support the view that vitamin D and VDR may have a small but potentially important role in melanoma susceptibility, and putatively a greater role in disease progression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19615888      PMCID: PMC2786912          DOI: 10.1016/j.ejca.2009.06.011

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  59 in total

1.  No evidence for reduced 25-hydroxyvitamin D serum level in melanoma patients.

Authors:  Jörg Reichrath; Kerstin Querings
Journal:  Cancer Causes Control       Date:  2004-02       Impact factor: 2.506

2.  Association of A vitamin D receptor polymorphism with sporadic breast cancer development.

Authors:  J E Curran; T Vaughan; R A Lea; S R Weinstein; N A Morrison; L R Griffiths
Journal:  Int J Cancer       Date:  1999-12-10       Impact factor: 7.396

3.  The polymorphic N terminus in human vitamin D receptor isoforms influences transcriptional activity by modulating interaction with transcription factor IIB.

Authors:  P W Jurutka; L S Remus; G K Whitfield; P D Thompson; J C Hsieh; H Zitzer; P Tavakkoli; M A Galligan; H T Dang; C A Haussler; M R Haussler
Journal:  Mol Endocrinol       Date:  2000-03

Review 4.  Vitamin D and cancer: effects of 1,25(OH)2D3 and its analogs on growth control and tumorigenesis.

Authors:  C M Hansen; L Binderup; K J Hamberg; C Carlberg
Journal:  Front Biosci       Date:  2001-07-01

5.  Functionally relevant polymorphisms in the human nuclear vitamin D receptor gene.

Authors:  G K Whitfield; L S Remus; P W Jurutka; H Zitzer; A K Oza; H T Dang; C A Haussler; M A Galligan; M L Thatcher; C Encinas Dominguez; M R Haussler
Journal:  Mol Cell Endocrinol       Date:  2001-05-25       Impact factor: 4.102

6.  Consequences of vitamin D receptor gene polymorphisms for growth inhibition of cultured human peripheral blood mononuclear cells by 1, 25-dihydroxyvitamin D3.

Authors:  E M Colin; A E Weel; A G Uitterlinden; C J Buurman; J C Birkenhäger; H A Pols; J P van Leeuwen
Journal:  Clin Endocrinol (Oxf)       Date:  2000-02       Impact factor: 3.478

Review 7.  Genetics and biology of vitamin D receptor polymorphisms.

Authors:  André G Uitterlinden; Yue Fang; Joyce B J Van Meurs; Huibert A P Pols; Johannes P T M Van Leeuwen
Journal:  Gene       Date:  2004-09-01       Impact factor: 3.688

8.  An assessment of a variant of the DNA repair gene XRCC3 as a possible nevus or melanoma susceptibility genotype.

Authors:  Chandra Gooptu Bertram; Rupert M Gaut; Jennifer H Barrett; Juliette Randerson-Moor; Linda Whitaker; Faye Turner; Veronique Bataille; Isabel dos Santos Silva; Anthony J Swerdlow; D Timothy Bishop; Julia A Newton Bishop
Journal:  J Invest Dermatol       Date:  2004-02       Impact factor: 8.551

Review 9.  Vitamin D and prostate cancer prevention and treatment.

Authors:  Tai C Chen; Michael F Holick
Journal:  Trends Endocrinol Metab       Date:  2003-11       Impact factor: 12.015

10.  A novel polymorphism in the 1A promoter region of the vitamin D receptor is associated with altered susceptibilty and prognosis in malignant melanoma.

Authors:  J A Halsall; J E Osborne; L Potter; J H Pringle; P E Hutchinson
Journal:  Br J Cancer       Date:  2004-08-16       Impact factor: 7.640

View more
  62 in total

1.  Melanocytic nevi, nevus genes, and melanoma risk in a large case-control study in the United Kingdom.

Authors:  Julia A Newton-Bishop; Yu-Mei Chang; Mark M Iles; John C Taylor; Bert Bakker; May Chan; Susan Leake; Birute Karpavicius; Sue Haynes; Elaine Fitzgibbon; Faye Elliott; Peter A Kanetsky; Mark Harland; Jennifer H Barrett; D Timothy Bishop
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-07-20       Impact factor: 4.254

Review 2.  New vitamin D analogs as potential therapeutics in melanoma.

Authors:  Paulina Szyszka; Michal A Zmijewski; Andrzej T Slominski
Journal:  Expert Rev Anticancer Ther       Date:  2012-05       Impact factor: 4.512

3.  The potential role of vitamin D in the progression of benign and malignant melanocytic neoplasms.

Authors:  Joel Pinczewski; Andrzej Slominski
Journal:  Exp Dermatol       Date:  2010-10       Impact factor: 3.960

Review 4.  Vitamin D signaling and melanoma: role of vitamin D and its receptors in melanoma progression and management.

Authors:  Andrzej T Slominski; Anna A Brożyna; Michal A Zmijewski; Wojciech Jóźwicki; Anton M Jetten; Rebecca S Mason; Robert C Tuckey; Craig A Elmets
Journal:  Lab Invest       Date:  2017-02-20       Impact factor: 5.662

Review 5.  Comprehensive field synopsis and systematic meta-analyses of genetic association studies in cutaneous melanoma.

Authors:  Foteini Chatzinasiou; Christina M Lill; Katerina Kypreou; Irene Stefanaki; Vasiliki Nicolaou; George Spyrou; Evangelos Evangelou; Johannes T Roehr; Elizabeth Kodela; Andreas Katsambas; Hensin Tsao; John P A Ioannidis; Lars Bertram; Alexander J Stratigos
Journal:  J Natl Cancer Inst       Date:  2011-06-21       Impact factor: 13.506

6.  From the bench to emerging new clinical concepts: Our present understanding of the importance of the vitamin D endocrine system (VDES) for skin cancer.

Authors:  Léa Trémezaygues; Jörg Reichrath
Journal:  Dermatoendocrinol       Date:  2011-01

7.  Update on the Epidemiology of Melanoma.

Authors:  Steven T Chen; Alan C Geller; Hensin Tsao
Journal:  Curr Dermatol Rep       Date:  2013-03-01

Review 8.  Vitamin D in cutaneous carcinogenesis: part II.

Authors:  Jean Y Tang; Teresa Fu; Christopher Lau; Dennis H Oh; Daniel D Bikle; Maryam M Asgari
Journal:  J Am Acad Dermatol       Date:  2012-11       Impact factor: 11.527

Review 9.  Vitamin D in cutaneous carcinogenesis: part I.

Authors:  Jean Y Tang; Teresa Fu; Christopher Lau; Dennis H Oh; Daniel D Bikle; Maryam M Asgari
Journal:  J Am Acad Dermatol       Date:  2012-11       Impact factor: 11.527

10.  Genetic variants in the vitamin D pathway genes VDBP and RXRA modulate cutaneous melanoma disease-specific survival.

Authors:  Jieyun Yin; Hongliang Liu; Xiaohua Yi; Wenting Wu; Christopher I Amos; Shenying Fang; Jeffrey E Lee; Jiali Han; Qingyi Wei
Journal:  Pigment Cell Melanoma Res       Date:  2016-01-29       Impact factor: 4.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.